Skip to main content
Web oficial de la Unión EuropeaWeb oficial de la UE
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-24

The potential of oligonucleotide submicrob positively charged, emulsion ocular delivery system for age related macular degeneration

Objetivo

Navigable wants to investigate co-operation possibilities between two well-reputed research institutes and some European Sum’s to form a consortium for the research development and marketing of a remedy to treat ARMD. Age-related Macular Degeneration, a common eye disorder, the leading cause of severe vision loss in people older than 50 years. The wet form is the most severe type of macular degeneration notwithstanding it affects only 10% of those with the diseases it accounts for 90% of the blindness caused by ARMD.Today about 400,000 new cases of wet ARMD occur each year in the USA and Europe. Products existing today can treat only 15% of the patients with this form. Navigable wants, on basis of its oligonucleotide and Ribosome submicronpositively charged emulsion delivery system, to form the above alliance to bring the fruit of the cooperation as a remedy to the market which will result in dramatically increase of the treatment of wet ARMD and thus enormously reducing this cause of blindness.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.

Para utilizar esta función, debe iniciar sesión o registrarse

Convocatoria de propuestas

Data not available

Régimen de financiación

EAW - Exploratory awards

Coordinador

NOVAGALI PHARMA SA
Aportación de la UE
Sin datos
Dirección
Rue Pierre Fontaine 1
91000 EVRY
Francia

Ver en el mapa

Coste total
Sin datos

Participantes (1)